EXPLORE!

NIH begins a new trial to evaluate HIV treatment regimens in pregnant women

  824 Views

eMediNexus    25 January 2018

The National Institutes of Health (NIH) has launched a large international study - IMPAACT 2010 or VESTED (Virologic Efficacy and Safety of Antiretroviral Therapy Combinations with TAF/TDF, EFV and DTG) – to evaluate the current preferred first-line regimen (efavirenz (EFV), lamivudine (3TC) or emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) for pregnant women recommended by the World Health Organization (WHO) and two regimens containing a newer drug, dolutegravir (DTG), and either tenofovir alafenamide (TAF)… (NIH, January 24, 2018)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.